Harvard Bioscience, Inc. (Nasdaq:HBIO) (the “Company”), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, has acquired 100% of the outstanding stock of Data Sciences International, Inc. (“DSI”) for approximately $70 million (subject to adjustment for net working capital and other customary adjustments).
DSI, a St. Paul, Minnesota-based life science research company, is a recognized leader in physiologic monitoring focused on delivering preclinical products, systems, services and solutions to its customers. Its customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs and government researchers. For the trailing 12 months (“TTM”) ended December 31, 2017, DSI had approximately $44 million in revenue.
EC M&A acted as financial advisor to Harvard Bioscience on this transaction